Your browser doesn't support javascript.
loading
A cost-benefit analysis of genetic screening test for breast cancer in Iran.
Meshkani, Zahra; Moradi, Najmeh; Aboutorabi, Ali; Farabi, Hiro; Moini, Nazi.
Afiliação
  • Meshkani Z; Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran. z_moshkani@yahoo.com.
  • Moradi N; Health Management and Economics Research Center, Iran University of Medical Sciences, 13833-19967, Tehran, Iran. z_moshkani@yahoo.com.
  • Aboutorabi A; Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Farabi H; Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran.
  • Moini N; Barts and The London Pragmatic Clinical Trial Unit, Centre for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
BMC Cancer ; 24(1): 279, 2024 Mar 01.
Article em En | MEDLINE | ID: mdl-38429685
ABSTRACT

BACKGROUND:

This study aimed to evaluate the implementation of the population- and family history (FH) -based screening for BReast CAncer (BRCA) in Iran, a country where less than 10% of breast cancer cases are attributable to a gene mutation.

METHODS:

This was an economic evaluation study. The Benefit-Cost Ratio (BCR) for genetic screening test strategies in Iranian women older than 30 was calculated. To this end, the monetary value of the test was estimated using the willingness-to-pay (WTP) approach using the contingent valuation method (CVM) by payment card. From a healthcare perspective, direct medical and non-medical costs were considered and a decision model for the strategies was developed to simulate the costs. A one-way sensitivity analysis assessed the robustness of the analysis. The data were analyzed using Excel 2010.

RESULTS:

660 women were included for estimating WTP and 2,176,919 women were considered in the costing model. The cost per genetic screening test for population- and FH-based strategies was $167 and $8, respectively. The monetary value of a genetic screening test was $20 and it was $27 for women with a family history or gene mutation in breast cancer. The BCR for population-based and FH-based screening strategies was 0.12 and 3.37, respectively. Sensitivity analyses confirmed the robustness of the results.

CONCLUSIONS:

This study recommends the implementation of a FH-based strategy instead of a population-based genetic screening strategy in Iran, although a cascade genetic screening test strategy should be evaluated in future studies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans País como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans País como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article